The EMRA Representative Council elected the most diverse Board of Directors in the organization’s 45-year history this fall, setting a new bar for inclusion in medicine.
Released in October 2019, CRASH-3 is the latest trial exploring the benefits of tranexamic acid, this time in traumatic brain injury. The bottom line: TXA hasn't been shown to reduce mortality.